Infrastructure to improve reliability of AMP-AD target hypotheses

Information

  • Research Project
  • 9681755
  • ApplicationId
    9681755
  • Core Project Number
    RF1AG057443
  • Full Project Number
    3RF1AG057443-01S2
  • Serial Number
    057443
  • FOA Number
    PA-18-591
  • Sub Project Id
  • Project Start Date
    9/15/2017 - 6 years ago
  • Project End Date
    8/31/2020 - 3 years ago
  • Program Officer Name
    PETANCESKA, SUZANA
  • Budget Start Date
    9/15/2018 - 5 years ago
  • Budget End Date
    8/31/2020 - 3 years ago
  • Fiscal Year
    2018
  • Support Year
    01
  • Suffix
    S2
  • Award Notice Date
    9/13/2018 - 5 years ago
Organizations

Infrastructure to improve reliability of AMP-AD target hypotheses

Project Summary/Abstract The Accelerating Medicines Partnership in Alzheimer?s Disease (AMP-AD) has developed over the past four years to support systems-level approaches to target discovery and validation. AMP-AD operates under an open science model in which all assets ? data, methods, computational disease models, and target hypotheses ? are rapidly shared with the broader research community to encourage independent evaluation and secondary use according to FAIR principles. Technical support for this dissemination is provided by the AMP-AD Knowledge Portal, through Sage Bionetworks. The AMP-AD Consortium has been highly successful in rapid, early distribution of genomic/multi-omic data; recent efforts have focused on sharing of disease models and target hypotheses. The Wall of Targets project (RF1-AG057443, PI-Mangravite), the parent grant to this supplement, is designed to support the consortium in aggregation and evaluation of AMP-AD target hypotheses. The Wall of Targets is being designed as a visual platform to aggregate target nominations from individual teams and to provide a consistent, data-driven mechanism to estimate confidence in these targets. This supplement will extend the goals of the parent project by establishing infrastructure for cloud-based analysis of the rich, large scale AMP-AD datasets that currently cannot be easily used in local settings. This will greatly improve the ability to independently evaluate evidence in support of AMP-AD target hypotheses within the consortium and by individual investigators at large and further democratize the use of the AMP-AD datasets according to the FAIR principles. !

IC Name
NATIONAL INSTITUTE ON AGING
  • Activity
    RF1
  • Administering IC
    AG
  • Application Type
    3
  • Direct Cost Amount
    1198266
  • Indirect Cost Amount
    687586
  • Total Cost
    1885852
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    866
  • Ed Inst. Type
  • Funding ICs
    NIA:1885852\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
  • Study Section Name
  • Organization Name
    SAGE BIONETWORKS
  • Organization Department
  • Organization DUNS
    830977117
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    981211042
  • Organization District
    UNITED STATES